• Nanion Technologies: イオンチャネル研究のスマートツール

    Nanion Technologies: イオンチャネル研究のスマートツール

  • CardioExcyte 96 SOL: 心筋の光ペーシング

    CardioExcyte 96 SOL: 心筋の光ペーシング

  • SURFE²R 96SE: ラベルフリーのトランスポーターHTS

    SURFE²R 96SE: ラベルフリーのトランスポーターHTS

  • 脂質二分子膜実験: Orbitシリーズ

    脂質二分子膜実験: Orbitシリーズ

Our Product Portfolio

SyncroPatch 384i

SyncroPatch 384i

Patchliner

Patchliner

Port-a-Patch

Port-a-Patch

Port-a-Patch mini

Port-a-Patch mini

CardioExcyte 96

CardioExcyte 96

FLEXcyte 96

FLEXcyte 96

SURFE²R 96SE

SURFE²R 96SE

SURFE²R N1

SURFE²R N1

Orbit 16

Orbit 16

Orbit Mini

Orbit Mini

Vesicle Prep Pro

Vesicle Prep Pro

2017 - Evaluation of the antimicrobial activity of the mastoparan Polybia-MPII isolated from venom of the social wasp Pseudopolybia vespiceps testacea (Vespidae, Hymenoptera)

icon pap   Port-a-Patch and   icon vpp   Vesicle Prep Pro publication in International Journal of Antimicrobial Agents (2017)

Authors: 
Silva J.C., Neto L.M., Neves R.C., Gonçalves J.C., Trentini M.M., Mucury-Filho R., Smidt K.S., Fensterseifer I.C., Silva O.N., Lima L.D., Clissa P.B., Vilela N., Guilhelmelli F., Silva L.P., Rangel M., Kipnis A., Silva-Pereira I., Franco O.L., Junqueira-Kipnis A.P., Bocca A.L., Mortari M.R.

 

Journal: 
International Journal of Antimicrobial Agents (2017) 49(2):167-175


Abstract: 

Mastoparans, a class of peptides found in wasp venom, have significant effects following a sting as well as useful applications in clinical practice. Among these is their potential use in the control of micro-organisms that cause infectious diseases with a significant impact on society. Thus, the present study describes the isolation and identification of a mastoparan peptide from the venom of the social wasp Pseudopolybia vespiceps and evaluated its antimicrobial profile against bacteria (Staphylococcus aureus and Mycobacterium abscessus subsp. massiliense), fungi (Candida albicans and Cryptococcus neoformans) and in vivo S. aureus infection. The membrane pore-forming ability was also assessed. The mastoparan reduced in vitro and ex vivo mycobacterial growth by 80% at 12.5 µM in infected peritoneal macrophages but did not affect the shape of bacterial cells at the dose tested (6.25 µM). The peptide also showed potent action against S. aureus in vitro (EC50 and EC90 values of 1.83 µM and 2.90 µM, respectively) and reduced the in vivo bacterial load after 6 days of topical treatment (5 mg/kg). Antifungal activity was significant, with EC50 and EC90 values of 12.9 µM and 15.3 µM, respectively, for C. albicans, and 11 µM and 22.70 µM, respectively, for C. neoformans. Peptides are currently attracting interest for their potential in the design of antimicrobial drugs, particularly due to the difficulty of micro-organisms in developing resistance to them. In this respect, Polybia-MPII proved to be highly effective, with a lower haemolysis rate compared with peptides of the same family.

Highlights:

- Polybia-MPII demonstrated potent activity against Staphylococcus aureus.
- Topical application of Polybia-MPII reduced the number of S. aureus in wounds.
- Polybia-MPII inhibited the growth of two medically important fungal pathogens.
- Polybia-MPII has potential to inhibit mycobacteria and to kill intracytoplasmic bacteria.
- The peptide presented lytic pore-forming activity on planar lipid bilayers.


Download here

Back

 

Nanion コーポレートブログ

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.